Bipolar disorder included in NICE work programme
October 27, 2003NHS professionals are to be given new clinical guidelines in two important areas of mental health as part of NICE's …
‘Bogus disease’ argument flares up again
October 27, 2003The British Medical Journal has accused the pharmaceutical industry of creating bogus disease areas in order to sell treatments.The respected …
Exanta promise for AstraZeneca
October 27, 2003AstraZeneca's new anticoagulant Exanta has shown to be more effective than warfarin in preventing stroke in patients suffering from arrhythmia.Exanta …
Little price competition in UK, says report
October 27, 2003Price competition is not a major factor in the UK prescription pharma market, according to a Department of Health report.The …
PFI hospitals failing, say unions
October 27, 2003Hospitals built under the private finance initiative are suffering from financial problems, bed shortages and poor design, according to a …
Patent challenge to Galen’s new product
October 27, 2003Galen faces a legal challenge in the US over the patent rights to a product it bought only last month.The …
OTC Claritin hits Schering-Plough
October 27, 2003Schering-Plough has admitted that it underestimated the effect that Claritin switching to an over-the-counter product would have on its profits.The …
Labour split over foundation trusts exposed
October 27, 2003Deep divisions within the Labour party over foundation hospitals have been further exposed in the House of Commons.More than 100 …
AstraZeneca picks Publicis and WPP as advertising partners
October 27, 2003AstraZeneca will work exclusively with Publicis and WPP agencies in the US following a rationalisation of its advertising partnerships.The review, …
Pension fund urges GSK to act on AIDS
October 27, 2003The world's largest pension fund has urged GlaxoSmithKline to step up its efforts to help combat the AIDS pandemic in …
Long-awaited diabetes NSF launched
October 27, 2003The long awaited diabetes national service framework has been launched with demanding new targets for the improvement of NHS services.By …
Investment banker to be Elan chief executive
October 27, 2003Elan
Kelly Martin, a former senior executive at Merrill Lynch, has been named chief executive of troubled Irish pharmaceutical company Elan.The …
Industry’s legal challenge to ‘arbitrary’ pricing
October 27, 2003European industry body EFPIA is seeking legal action against the Italian Government new reimbursement and pricing policy, which it believes …
Latest content
FibroFind appoints Lee Borthwick as CEO
